Everything is backwards with fallen elites. They weren't looking to save humanity. They were looking for a vaccine to save themselves. Since they are still pushing the scamdemic they haven't found it.
There are reports claiming that as of October 7, 2024, the option to specify bivalent COVID-19 vaccines in the VAERS input form has been removed. However, official confirmations of this change are not widely available. Changes in the reporting system, such as focusing on newer vaccines like those targeting XBB variants, could be causing confusion.
If you encounter such difficulties, it would be advisable to contact VAERS support directly for clarification or check the latest forms to ensure you're using the most up-to-date reporting system
Interesting Ai said "reports claiming" bivalents have been removed on Oct 7. This must be my report of VAX TYPE option has been removed for submitters. As far as I know nobody else has made this observation but me. This is even more shady than JJ Janssen taking down their lot number expiration look-up tool from their website on the day JJ was pulled off the shelves. Janssen reports are still being newly published to this very day...
In Germany, bivalent COVID-19 vaccines were introduced from the end of 2022. They target both the original wild-type virus and the Omicron variants, Here's an overview of the main bivalent COVID-19 vaccines and their rollout:
Bivalent Vaccine from BioNTech/Pfizer (Comirnaty®):
Approval: by the European Medicines Agency (EMA) on September 1, 2022. Availability: In Germany, the vaccine became available shortly after its approval, and the first vaccinations began in the fall of 2022. Further Variants: Over time, additional bivalent versions of Comirnaty® followed, targeting Omicron subvariants such as BA.4 and BA.5, which were also administered starting in the fall of 2022.
Bivalent Vaccine from Moderna (Spikevax®):
Approval: On September 1, 2022, the EMA also approved Moderna's bivalent vaccine. Availability: Moderna's bivalent vaccine was administered in Germany starting in the fall of 2022. Further Variants: Moderna also introduced further bivalent versions targeting Omicron subvariants BA.4/BA.5.
The bivalent vaccines were mainly used for booster vaccinations to offer improved protection against newer virus variants. (From September 2022 to April 2023, around 62.6% of the population in Germany had received a COVID-19 booster vaccination. Additionally, about 15.2% of people had received a second booster shot)
These bivalent vaccines were primarily recommended for people aged 12 and older, as well as for high-risk groups.
The administration of the monovalent COVID-19 vaccine was discontinued in Germany in April 2023.
Pretty soon everyone who is vaccinated is going to know someone who is really fucked up by the vaccines. It will be interesting to see how they deal with it. Because they’re next.
Question 1: What happened to the country codes in VAERS?
Answer: The country codes in VAERS reports were removed following requests from European regulators. This change specifically impacted foreign reports submitted to VAERS that might not comply with European privacy regulations, such as the GDPR. In addition to country codes, other fields like free-text symptom narratives, lab data, and medical history details were also removed. These changes only affected foreign reports, while domestic U.S. reports remained unaffected
Question 2: What does this have to do with privacy regulations? Answer: The removal of country codes from VAERS data is tied to privacy regulations, particularly the stringent requirements of European laws like the GDPR. These regulations demand the protection of personal data, and country codes could theoretically be used to identify individuals when combined with other information like free-text narratives and medical histories. By removing such details, the aim was to ensure that data sent to VAERS from Europe complies with privacy laws, minimizing the risk of unauthorized disclosure of personal information.
Question 3:
How can I now identify which data comes from Denmark? Answer: Since the country codes have been removed from VAERS reports, it is no longer possible to directly identify which reports originate from Denmark or any other specific country. This change was implemented to comply with European privacy regulations, such as the GDPR. Without country codes or other geographical identifiers, the data can only be analyzed in a general sense. If you need to analyze data specifically from Denmark, you might consider looking for publicly available datasets or national monitoring systems that provide geographical information. VAERS itself no longer offers a way to filter reports by country of origin
Question 4: How can European scientists aiming to investigate the safety profiles of COVID-19 vaccines do this research?
European scientists aiming to investigate the safety profiles of COVID-19 vaccines should adopt a methodical approach to ensure reliable and meaningful results. Here are some suggestions for how they might proceed: 1) Data Integration: Researchers should combine VAERS data with national sources, such as the Paul-Ehrlich-Institut (PEI) in Germany (underreported, Lisa) or EudraVigilance at the EU level. This integration will enable more comprehensive analyses and help identify differences in the safety profiles of vaccines. The PEI regularly publishes safety reports that provide valuable insights into vaccine adverse events in Germany. (the national database of the PEI was temporarily suspended to meet technical requirements, Lisa)
2) Focus on Batch Analyses: Research should concentrate on specific vaccine batches, such as the "yellow" and "blue" batches, to examine differences in reported adverse events. It would be beneficial to compare statistics on reports from various countries to identify potential safety issues.
Albert wonderful work as ever thank you. The psychopathic 'elites' are disappearing up their own backsides faster than ever.
GOD's blessings to you WTE. Deeply grateful for the work you do ...
Everything is backwards with fallen elites. They weren't looking to save humanity. They were looking for a vaccine to save themselves. Since they are still pushing the scamdemic they haven't found it.
ACIP red light for bivalen jab Sept 1st 2022
https://totalityofevidence.com/timeline/fda-approves-bivalent-vaccine-on-faith-not-data/
Aug 18, 2023 the original monovalent jabs nolonger available in US
https://totalityofevidence.com/timeline/fda-monovalent-mrna-vaccines-no-longer-authorised-in-us/
Same sort of thing with 'childhood vaccines.'
Thank you, WTE!!
Not vetted but . . . . here's the CDC's newest public scam Oct 4, 2024 - https://www.cbsnews.com/news/new-cdc-website-shows-if-covid-or-flu-is-on-the-rise-in-2024/ . Not reporting numbers anywhere I've checked and I've checked.
AI gives the following answer:
There are reports claiming that as of October 7, 2024, the option to specify bivalent COVID-19 vaccines in the VAERS input form has been removed. However, official confirmations of this change are not widely available. Changes in the reporting system, such as focusing on newer vaccines like those targeting XBB variants, could be causing confusion.
If you encounter such difficulties, it would be advisable to contact VAERS support directly for clarification or check the latest forms to ensure you're using the most up-to-date reporting system
(CDC)(Moderna).
Interesting Ai said "reports claiming" bivalents have been removed on Oct 7. This must be my report of VAX TYPE option has been removed for submitters. As far as I know nobody else has made this observation but me. This is even more shady than JJ Janssen taking down their lot number expiration look-up tool from their website on the day JJ was pulled off the shelves. Janssen reports are still being newly published to this very day...
with the help of AI:
In Germany, bivalent COVID-19 vaccines were introduced from the end of 2022. They target both the original wild-type virus and the Omicron variants, Here's an overview of the main bivalent COVID-19 vaccines and their rollout:
Bivalent Vaccine from BioNTech/Pfizer (Comirnaty®):
Approval: by the European Medicines Agency (EMA) on September 1, 2022. Availability: In Germany, the vaccine became available shortly after its approval, and the first vaccinations began in the fall of 2022. Further Variants: Over time, additional bivalent versions of Comirnaty® followed, targeting Omicron subvariants such as BA.4 and BA.5, which were also administered starting in the fall of 2022.
Bivalent Vaccine from Moderna (Spikevax®):
Approval: On September 1, 2022, the EMA also approved Moderna's bivalent vaccine. Availability: Moderna's bivalent vaccine was administered in Germany starting in the fall of 2022. Further Variants: Moderna also introduced further bivalent versions targeting Omicron subvariants BA.4/BA.5.
The bivalent vaccines were mainly used for booster vaccinations to offer improved protection against newer virus variants. (From September 2022 to April 2023, around 62.6% of the population in Germany had received a COVID-19 booster vaccination. Additionally, about 15.2% of people had received a second booster shot)
These bivalent vaccines were primarily recommended for people aged 12 and older, as well as for high-risk groups.
The administration of the monovalent COVID-19 vaccine was discontinued in Germany in April 2023.
Anecdotal, I know, but it was following the Moderna bivalent (UK) that I noticed more people short of breath or catching “covid” shortly after.
Pretty soon everyone who is vaccinated is going to know someone who is really fucked up by the vaccines. It will be interesting to see how they deal with it. Because they’re next.
A lot of them, the ones that worked on these bio weapons, were useful idiots to the masterminds of this crime.
With the help of AI:
I don´t know if your are familiar with this.
Question 1: What happened to the country codes in VAERS?
Answer: The country codes in VAERS reports were removed following requests from European regulators. This change specifically impacted foreign reports submitted to VAERS that might not comply with European privacy regulations, such as the GDPR. In addition to country codes, other fields like free-text symptom narratives, lab data, and medical history details were also removed. These changes only affected foreign reports, while domestic U.S. reports remained unaffected
Question 2: What does this have to do with privacy regulations? Answer: The removal of country codes from VAERS data is tied to privacy regulations, particularly the stringent requirements of European laws like the GDPR. These regulations demand the protection of personal data, and country codes could theoretically be used to identify individuals when combined with other information like free-text narratives and medical histories. By removing such details, the aim was to ensure that data sent to VAERS from Europe complies with privacy laws, minimizing the risk of unauthorized disclosure of personal information.
Question 3:
How can I now identify which data comes from Denmark? Answer: Since the country codes have been removed from VAERS reports, it is no longer possible to directly identify which reports originate from Denmark or any other specific country. This change was implemented to comply with European privacy regulations, such as the GDPR. Without country codes or other geographical identifiers, the data can only be analyzed in a general sense. If you need to analyze data specifically from Denmark, you might consider looking for publicly available datasets or national monitoring systems that provide geographical information. VAERS itself no longer offers a way to filter reports by country of origin
Question 4: How can European scientists aiming to investigate the safety profiles of COVID-19 vaccines do this research?
European scientists aiming to investigate the safety profiles of COVID-19 vaccines should adopt a methodical approach to ensure reliable and meaningful results. Here are some suggestions for how they might proceed: 1) Data Integration: Researchers should combine VAERS data with national sources, such as the Paul-Ehrlich-Institut (PEI) in Germany (underreported, Lisa) or EudraVigilance at the EU level. This integration will enable more comprehensive analyses and help identify differences in the safety profiles of vaccines. The PEI regularly publishes safety reports that provide valuable insights into vaccine adverse events in Germany. (the national database of the PEI was temporarily suspended to meet technical requirements, Lisa)
2) Focus on Batch Analyses: Research should concentrate on specific vaccine batches, such as the "yellow" and "blue" batches, to examine differences in reported adverse events. It would be beneficial to compare statistics on reports from various countries to identify potential safety issues.